Recent and future advances in anticancer drug delivery: an interview with Khaled Greish

Ther Deliv. 2018 May 1;9(6):409-412. doi: 10.4155/tde-2018-0019.

Abstract

Khaled Greish speaks to Hannah Makin, Commissioning Editor: Khaled Greish is Associate Professor of Molecular Medicine, and head of the Nano-research unit, at Princes Al-Jawhara Center, Arabian Gulf University, Kingdom of Bahrain. His previous appointments included Senior lecturer of Pharmacology at the University of Otago, New Zealand, and Assistant Professor of Pharmaceutical Chemistry at University of Utah (UT, USA). He has published >70 peer reviewed papers, and ten book chapters in the field of targeted anticancer drug delivery. Controlled Release Society (CRS) awarded him the CRS Postdoctoral Achievement Award in 2008 and in 2010; he was elected as member of the CRS College of Fellows. In recognition of his research, University of Otago awarded him "Early Career Awards for Distinction in Research" in 2014. His research focuses on nanomedicine, tumor vascular biology and anticancer drug discovery/development.

Keywords: anticancer drug delivery; drug delivery; nanomedicine.

Publication types

  • Interview

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Delayed-Action Preparations / administration & dosage
  • Drug Carriers / chemistry*
  • Humans
  • Immunotherapy / methods
  • Micelles*
  • Nanomedicine / methods*
  • Nanoparticles / chemistry
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology

Substances

  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Drug Carriers
  • Micelles
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor